Aurora kinase inhibitors: Progress towards the clinic

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1573-0646

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Aurora kinase inhibitors: Progress towards the clinic ; volume:30 ; number:6 ; day:18 ; month:2 ; year:2012 ; pages:2411-2432 ; date:12.2012
Investigational new drugs ; 30, Heft 6 (18.2.2012), 2411-2432, 12.2012

Creator: Kollareddy, Madhu
Zheleva, Daniella
Dzubak, Petr
Brahmkshatriya, Pathik Subhashchandra
Lepsik, Martin
Hajduch, Marian

Contributor: SpringerLink (Online service)

DOI: 10.1007/s10637-012-9798-6

URN: urn:nbn:de:101:1-2019091908225201754564

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:33 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Kollareddy, Madhu
Zheleva, Daniella
Dzubak, Petr
Brahmkshatriya, Pathik Subhashchandra
Lepsik, Martin
Hajduch, Marian
SpringerLink (Online service)

Other Objects (12)

Mitotic drivers—inhibitors of the Aurora B Kinase

Canine osteosarcoma cells exhibit resistance to aurora kinase inhibitors

Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer

Hochschulschrift

Untersuchungen zur Resistenz gegenüber Aurora Kinase Inhibitoren in Myc-induzierten Lymphomen

Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells

Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors

Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells

Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma

Progress toward resistance mechanism to epidermal growth factor receptor tyrosine kinase inhibitor

Discovery of a Novel Pseudo‐Natural Product Aurora Kinase Inhibitor Chemotype through Morphological Profiling

ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib

Using ZINC08918027 inhibitor to determine Aurora kinase-chromosomal passenger complex isoforms in mouse oocytes

Mitotic drivers—inhibitors of the Aurora B Kinase

Canine osteosarcoma cells exhibit resistance to aurora kinase inhibitors

Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer

Hochschulschrift

Untersuchungen zur Resistenz gegenüber Aurora Kinase Inhibitoren in Myc-induzierten Lymphomen

Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells

Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors

Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells

Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma

Progress toward resistance mechanism to epidermal growth factor receptor tyrosine kinase inhibitor

Discovery of a Novel Pseudo‐Natural Product Aurora Kinase Inhibitor Chemotype through Morphological Profiling

ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib

Using ZINC08918027 inhibitor to determine Aurora kinase-chromosomal passenger complex isoforms in mouse oocytes

Mitotic drivers—inhibitors of the Aurora B Kinase

Canine osteosarcoma cells exhibit resistance to aurora kinase inhibitors

Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer

Hochschulschrift

Untersuchungen zur Resistenz gegenüber Aurora Kinase Inhibitoren in Myc-induzierten Lymphomen

Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells

Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors

Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells

Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma

Progress toward resistance mechanism to epidermal growth factor receptor tyrosine kinase inhibitor

Discovery of a Novel Pseudo‐Natural Product Aurora Kinase Inhibitor Chemotype through Morphological Profiling

ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib

Using ZINC08918027 inhibitor to determine Aurora kinase-chromosomal passenger complex isoforms in mouse oocytes

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Aurora kinase inhibitors: Progress towards the clinic

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Mitotic drivers—inhibitors of the Aurora B Kinase

Canine osteosarcoma cells exhibit resistance to aurora kinase inhibitors

Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer

Untersuchungen zur Resistenz gegenüber Aurora Kinase Inhibitoren in Myc-induzierten Lymphomen

Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells

Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors

Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells

Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma

Progress toward resistance mechanism to epidermal growth factor receptor tyrosine kinase inhibitor

Discovery of a Novel Pseudo‐Natural Product Aurora Kinase Inhibitor Chemotype through Morphological Profiling

ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib

Using ZINC08918027 inhibitor to determine Aurora kinase-chromosomal passenger complex isoforms in mouse oocytes

Mitotic drivers—inhibitors of the Aurora B Kinase

Canine osteosarcoma cells exhibit resistance to aurora kinase inhibitors

Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer

Untersuchungen zur Resistenz gegenüber Aurora Kinase Inhibitoren in Myc-induzierten Lymphomen

Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells

Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors

Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells

Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma

Progress toward resistance mechanism to epidermal growth factor receptor tyrosine kinase inhibitor

Discovery of a Novel Pseudo‐Natural Product Aurora Kinase Inhibitor Chemotype through Morphological Profiling

ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib

Using ZINC08918027 inhibitor to determine Aurora kinase-chromosomal passenger complex isoforms in mouse oocytes

Mitotic drivers—inhibitors of the Aurora B Kinase

Canine osteosarcoma cells exhibit resistance to aurora kinase inhibitors

Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer

Untersuchungen zur Resistenz gegenüber Aurora Kinase Inhibitoren in Myc-induzierten Lymphomen

Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells

Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors

Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells

Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma

Progress toward resistance mechanism to epidermal growth factor receptor tyrosine kinase inhibitor

Discovery of a Novel Pseudo‐Natural Product Aurora Kinase Inhibitor Chemotype through Morphological Profiling

ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib

Using ZINC08918027 inhibitor to determine Aurora kinase-chromosomal passenger complex isoforms in mouse oocytes

Related objects

Reset password